logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
NLSP
NLS Pharmaceutics AG
2.91
2 x 0.57
2 x 0.99
bid
ask
+
0.00
0.00%
09:30 AM
timesize
Ytd-86.21%
1y-92.46%
2.91
day range
3.51
0.76
52 week range
43.40
Open3.31Prev Close2.91Low2.91High3.51Mkt Cap919.60K
Vol113.99KAvg Vol74.12KEPS-17.40P/E-0.17Forward P/E-3.60
Beta0.14Short Ratio0.15Inst. Own19.40%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg18.99200-d Avg19.401yr Est0.00

NLSP News

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
prnewswire.com
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmace

ZURICH , Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Sw

NLS Pharmaceutics Ltd. and Kadimastem Ltd.
prnewswire.com
NLS Pharmaceutics Ltd. and Kadimastem Ltd.

Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
prnewswire.com
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by So

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
prnewswire.com
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes P

ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
prnewswire.com
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Pro

ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS"

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Tra

ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP)

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipa

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
prnewswire.com
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.  (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS"

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
prnewswire.com
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary

Vote clears final corporate milestone, paving the way for the closing of the merger and the combined

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
prnewswire.com
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection

ZURICH and NESS ZIONA, Israel , Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
prnewswire.com
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment

Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United Stat

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
prnewswire.com
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Appr

Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30,

NLS Pharmaceutics CEO Issues Letter to Shareholders
prnewswire.com
NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH , June 16, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd.  (NASDAQ: NLSP), a Swiss clinical-sta

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
prnewswire.com
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Wit

ZURICH , May 21, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP), a Swiss clinical-stage

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
prnewswire.com
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentan

Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therap

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
accessnewswire.com
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity

The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS New

NLS Pharmaceutics CEO Issues Letter to Shareholders
prnewswire.com
NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH , March 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stag

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
prnewswire.com
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of i

ZÜRICH, Switzerland , Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: N

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
prnewswire.com
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes

Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes With